With a revenue increase of 1.31% in the second quarter 2026, year on year to cumulative value of $2,912 million, Revvity Inc's revenue per employee grew on a trailing twelve months basis to $ 264,710. The productivity of Revvity Inc's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 345 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 2717, from total ranking in previous quarter at 3065. Revvity Inc has 11,000 employees.
In a significant move for Alzheimer s disease management, Revvity, Inc. (NYSE: RVTY) has announced the launch of its groundbreaking in-vitro diagnostic tool, the EURORealTime™ APOE assay. This innovative assay, now available in various European countries that accept the CE mark, is designed to accurately genotype the APOE gene, a crucial step in assessing a patient’s risk for complications prior to initiating anti-amyloid therapies. Understanding the APOE Gene s Role in Alzheimer s Disease Research has long established the importance of the APOE gene in Alzheimer s disease. Genotyping the APOE gene is a crucial step in understanding an individual s predisposition to the disease. The presence of certain alleles, particularly APOE ε4, is associated with a significantly higher risk of developing Alzheimer’s disease and its associated complications. By providing a precise genotyping solution, Revvity is positioning itself as a leader in preventative healthcare within the realm of neurological disorders. Therapeutic Advancements and Their Implications The launch of the EURORealTime™ APOE assay coincides with an evolving landscape of Alzheimer s treatment options. With new disease-modifying drugs entering the market, accurately determining a patient’s risk profile has become essential to tailor therapies that minimize potential side effects. For instance, anti-amyloid therapies, while promising, come with a range of risks, including brain edema. The ability to genotype patients before treatment allows for a more nuanced approach, improving patient outcomes and possibly reducing the overall burden on healthcare systems.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
